Base to Base biotech podcast 22: A new treatment for dry AMD and tackling peanut allergies

This week, we talk about new treatments for wet dry age-related macular degeneration (AMD) with Judith Greciet, CEO of PulseSight Therapeutics, and there’s a conversation with Maite Agüeros, CEO and co-founder of InnoUp Farma about, among other things, peanut allergies.

Interview times:

03:24 PulseSight

20:43 InnoUp

Tackling dry AMD

PulseSight Therapeutics SAS, an ophthalmology biotech company developing non-viral vectorised therapies with minimally-invasive delivery technology, recently announced the first patient has been successfully dosed in its phase I clinical trial (PST-611-CT1) aiming to assess safety and tolerability of its lead programme, PST-6 ...